TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy
Clinical trial NCT02186301 · TERMINATED
Trial details
- NCT number
- NCT02186301
- Sponsor
- Clovis Oncology, Inc.
- Status
- TERMINATED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-11-01
- Primary completion
- 2017-06-28
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.